#Sweden #Stockholm #Eisai #Leqembi #BioArctic

New Insights from the LEADER Study on Leqembi®

Recent findings presented at the Alzheimer's Association International Conference (AAIC) 2026 unveil significant results from the real-world LEADER study concerning Leqembi®, an innovative treatment for early Alzheimer's disease. According to the results, more than 83% of participants showed either stability in their disease status or an improvement throughout an average treatment period of 17 months. This study adds to the ongoing dialogue surrounding effective solutions for Alzheimer's disease management, emphasizing both the safety and efficacy of Leqembi.

Overview of the LEADER Study

The LEADER study stands out as a comprehensive three-year multicenter, retrospective analysis conducted across diverse clinical settings in the United States. It was meticulously designed to assess various factors including Leqembi's long-term utilization, maintenance treatment transitions, safety outcomes, and cognitive evaluations among patients diagnosed with early-stage Alzheimer's disease. A total of 432 patients participated in this real-world analysis, all of whom received at least seven infusions of Leqembi by May 2026.

Key Demographics

Among the patients evaluated, the average age was 74 years, with a notable majority of female participants (55.8%). The analysis revealed that 63.9% of patients were diagnosed with mild cognitive impairment (MCI) due to Alzheimer's, while 36.1% were classified with mild Alzheimer's dementia.

Treatment Duration and Efficacy

On average, patients received treatment for approximately 520 days, with an average of 26 infusions administered over this period. The outcomes were clearly defined, with two major metrics being closely observed:

• - Stable Patients: Those who maintained their disease stage from the onset of treatment (either MCI or mild dementia).
• - Improved Patients: Those who transitioned from mild Alzheimer's dementia to MCI due to Alzheimer's during the treatment timeframe.

The results highlighted that 75.9% of participants remained stable over the study duration, demonstrating the sustained benefits of Leqembi in real-world applications. Additionally, around 6.6% of patients showcased an improvement in their cognitive status. An impressive figure emerged from the study as nearly 87% of the participants opted to continue their Leqembi treatment, thereby showcasing their confidence in the drug's effectiveness.

APOE Genotype Analysis

An in-depth examination of the APOE genotype indicated that approximately 81.7% of APOE ε4 heterozygotes and 81.0% of APOE ε4 homozygotes maintained stable or improved stages during their treatment with Leqembi. Notably, variations in the group's overall performance reflected no significant disparities across sex, race, ethnicity, or genotype demographics.

Safety Observations

In terms of safety, the trial adhered to safety profiles consistent with FDA-approved guidelines. Amyloid-related imaging abnormalities (ARIA) were observed in 12.3% of patients, including ARIA-E and ARIA-H events. Most of these cases were categorized as mild or asymptomatic. The intricate details surrounding them, such as the absence of severe ARIA reports during the maintenance therapy phase, add a layer of reassurance concerning the drug's safety.

Conclusion

The real-world LEADER study findings bolster the argument for Leqembi as a promising treatment option for early Alzheimer's disease, with sustained stability and noticeable improvements in cognitive function for a significant proportion of patients. These insights will undoubtedly be invaluable as the medical community continues to seek effective therapies for this challenging ailment, revealing new possibilities for enhancing patients' quality of life. As we delve deeper into the intricacies of Alzheimer's disease management, studies like LEADER underscore the imperative need for continued research and investment in innovative treatment options.

BioArctic, in collaboration with Eisai, is dedicated to further advancing Alzheimer's care and striving for groundbreaking developments, making Leqembi a beacon of hope for patients and their families affected by this progressive disease.